Drug to Drug Interaction Study With ASP1941 and Metformin

Inclusion Criteria: * Subjects with type 2 diabetes * Stable disease under metformin monotherapy (between 1500-3000 mg/day) or dual therapy with metformin (1500-3000 mg/day) and a Sulfonylureum Derivative (SUD) for at least 3 months * Fasting Serum Glucose: 7-11.5 mmol/l (after wash-out) * Stable Fasting Blood Glucose (FBG) at the end of wash-out * BMI between 18.5 and 40.0 kg/m2, inclusive Exclusion Criteria: * Subjects with type 1 diabetes * Any diabetes related macro-complications, painful diabetic neuropathy, diabetic macular edema or diabetic proliferative retinopathy * Clinical significant renal disease (CLcr \<60 ml/min as assessed during a 24h creatinine clearance on Day-2 * Recent evidence (e.g. within the last 6 months) of severe hypoglycemia, for example plasma glucose \<3 mmol/l (\<55 mg/dl) or requiring hospitalization * Pulse \<40 or \>90; Systolic Blood Pressure \>160 mmHg; Diastolic Blood Pressure \> 100 mmHg